CD38 and Miyoshi myopathy: With the advent of new therapeutic agents, such as proteasome inhibitors (PIs), immunomodulatory drugs (IMIDs), and anti-CD38 monoclonal antibodies, the overall survival of MM patients has significantly improved [4-6].